UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report (Date of earliest event reported): March 22, 2005
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
|
DELAWARE |
|
0-19731 |
|
94-3047598 |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer |
333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA
(Address of principal executive offices)
94404
(Zip Code)
(650) 574-3000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFD 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SECTION 1 – REGISTRANT’S BUSINESS AND OPERATIONS
Item 1.01 Entry into a Material Definitive Agreement.
On March 22, 2005, Gilead Sciences, Inc. entered into a licensing agreement with Japan Tobacco Inc. (JT) for the exclusive rights to develop and commercialize a novel HIV integrase inhibitor (JTK-303) in all countries of the world, excluding Japan, where JT will retain rights. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
A copy of the press release further describing this licensing agreement is filed as Exhibit 99.1 to this report and is incorporated herein by reference.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release, dated March 22, 2005, entitled “Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor” |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
GILEAD SCIENCES, INC. |
|
|
|
|
(Registrant) |
|
|
|
|
|
|
|
|
Dated: March 22, 2005 |
By: |
/s/ John C. Martin |
|
|
|
|
John C. Martin |
|
|
|
|
President and Chief Executive Officer |
|
3
Exhibit Index
|
Exhibit |
|
Description |
|
99.1 |
|
Press Release, dated March 22, 2005, entitled “Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor” |
4